Neurocognition and early overtreatment in congenital hypothyroidism detected by neoantal screening

PARDO CAMPOS ML ; BERGADA I; MENDEZ V,; CHIESA A ; ENACAN R,; PAPENDIECK P

CABA

Congreso; XI Congreso Latinoamericano de errores congénitos del metabolismo y pesquisa neonatal; 2019

Sociedad latinoamericana de errores congenitos y pesquisa neonatal (SLEIMPN)

Early diagnosis and treatment of congenital hypothyroidism (CH) prevents mental retardation. Although initial treatment with high doses of levothyroxine (LT4) is recommended, moderate hypertiroxinemia with suppressed TSH during the first months of some patients is difficult to avoid. If this is innocuous or constitutes a risk factor for neurocognitive impairment is controversial.Objective To evaluate the cognitive outcome at age 9-10 years of early detected and treated CH in whom suppressed TSH and moderate hyperthyroxinemia were present during the first six months of treatment.Patients and Methods:We retrospectively reviewed data on age, TSH and T4 levels at diagnosis, LT4 initial doses, etiology, symptoms of hyperthyroidism and T4 levels attained at 2 and 6 months of 35CH patients early detected and regularly followed up.Patients were considered overtreated (OT) if TSH was persistently 40 uUI/ml(OT: 89,5%, NOT:93,8%) and T4